Saha Lekha, Kaur Sharonjeet, Saha Pradip Kumar
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
J Pharmacol Pharmacother. 2013 Jul;4(3):187-91. doi: 10.4103/0976-500X.114597.
Clomiphene citrate (CC) has been the gold-standard drug for ovulation induction in polycystic ovary syndrome (PCOS), but still CC resistance is seen in approximately 15-40% in women with PCOS. N-acetyl cysteine (NAC), a safe and cheap drug available in the market many years ago as mucolytic agent, was found to have a role in infertility management. Recently, some reports discussed the possible beneficial effects of NAC on ovulation. The biological properties of the NAC make this drug a potential candidate for its use in the infertility treatment, especially in the PCOS in inducing or augmenting ovulation. An updated electronic search was performed through PUBMED, MEDLINE, and COCHRANE and focused on peer-reviewed, full text, randomized controlled trials, and observational cohort or case-control studies for role of NAC in CC-resistant PCOS. Thorough search through all the clinical studies showed mixed results. Studies with positive results showed improvement in induction of ovulation as compared to negative studies showing contrary results. More randomized clinical trials are still needed to establish its definitive role in CC-resistant PCOS.
枸橼酸氯米芬(CC)一直是多囊卵巢综合征(PCOS)促排卵的金标准药物,但仍有大约15%-40%的PCOS女性存在CC抵抗。N-乙酰半胱氨酸(NAC)是一种多年前就已作为黏液溶解剂在市场上销售的安全且廉价的药物,人们发现它在不孕症治疗中发挥着作用。最近,一些报告讨论了NAC对排卵可能的有益作用。NAC的生物学特性使其成为不孕症治疗的潜在候选药物,尤其是在PCOS中诱导或增强排卵方面。通过PUBMED、MEDLINE和COCHRANE进行了最新的电子检索,重点关注同行评审的全文、随机对照试验以及关于NAC在CC抵抗性PCOS中作用的观察性队列或病例对照研究。对所有临床研究的全面检索显示结果不一。与显示相反结果的阴性研究相比,有阳性结果的研究显示促排卵有改善。仍需要更多的随机临床试验来确定其在CC抵抗性PCOS中的明确作用。